New-onset and relapsing glomerular diseases related to COVID-19 vaccination

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021 Aug 25;50(4):524-528. doi: 10.3724/zdxbyxb-2021-0156.

Abstract

COVID-19 vaccine, as one of the critical measures to control the pandemic, has been administered in nearly all countries. However, the new-onset and relapsing glomerular diseases associated with COVID-19 vaccination have become a new concern. Both mRNA vaccine and inactivated vaccine may cause new-onset and relapsing glomerular diseases; these diseases would occur after the first dose vaccination or the second dose. New-onset glomerular disease is mainly minimal change glomerulopathy, which is mostly sensitive to steroid, while relapsing cases have good prognosis, and some cases can be spontaneously remitted. The pathogenesis of these vaccine-associated diseases is possibly due to the humoral and cellular immune responses. In this article, we provide a general review of the new-onset and relapsing glomerular diseases related to COVID-19 vaccination, and make suggestions for patients with kidney diseases to receive COVID-19 vaccination.

Keywords: Adverse reaction; Coronavirus disease 2019; Glomerulopathy; New-onset; Relapsing; Review; Vaccines.

MeSH terms

  • COVID-19 Vaccines
  • COVID-19*
  • Humans
  • Kidney Diseases*
  • SARS-CoV-2
  • Vaccination / adverse effects

Substances

  • COVID-19 Vaccines

Grants and funding

浙江省重点研发计划(2019C03028)